Martin Shkreli

Plant-based meat company Beyond Meat Inc (NASDAQ:BYND) is set to report third-quarter financial results Monday after market close. The report comes after the company delayed its earnings report, originally planned for last week. Here are the earnings estimates and key items to watch. Earnings...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" Martin Shkreli said he still likes the stock.  SRPT stock is crashing. See the real-time price...

Gov. Ron DeSantis (R) expressed concerns regarding OpenAI’s critical importance to the economy and the broader tech ecosystem. Not ‘Too Big To Fail’ On Sunday, in a post on X, DeSantis signaled his unease, citing a Wall Street Journal piece that asked if the AI giant was becoming...

Investor Martin Shkreli, popularly known as “Pharma Bro,” is criticizing President Donald Trump’s latest decision to acquire equity stakes in quantum computing stocks. The Government ‘Is Not A VC’ On Thursday, in a post on X, Shkreli slammed the move, being...

Beyond Meat, Inc. (NASDAQ:BYND) shares ripped higher on Wednesday as traders discussed a possible "short-squeeze" due to outsized short interest in the stock.  Beyond Meat can count a new high-profile short-seller among its ranks: Martin Shkreli.  BYND stock is squeezing higher. See the real-time...

Martin Shkreli, known for his outspoken views in finance, has been shorting quantum computing stocks IonQ, Inc. (NYSE:IONQ), D-Wave Quantum, Inc. (NYSE:QBTS), Rigetti Computing, Inc. (NASDAQ:RGTI), and Quantum Computing Inc. (NASDAQ:QUBT), regularly mocking what he sees as overvaluation and...

Investor Martin Shkreli, popularly referred to as the “Pharma Bro,” has once again criticized investors who are bearish on Tesla Inc. (NASDAQ:TSLA), even comparing their bets against the electric vehicle giant to several common psychiatric delusions. TSLA shares are sliding on...

Known in the past as the "Pharma Bro" for his ties to the pharmaceutical industry, Martin Shkreli is known these days for shorting individual stocks or entire sectors, like a recent bet against public quantum computing companies. In a potential rare sign of support, Shkreli is speaking out against...

Hedge fund manager George Noble posted a bold criticism of Opendoor Technologies, Inc.’s (NASDAQ:OPEN) latest product rollouts in a social media post on Wednesday night.  OPEN stock is moving. See the real-time price action here.  Earlier on Wednesday, Opendoor CEO Kaz Nejatian...

Investor Martin Shkreli came out in support of the $100 billion investment pledge made by chipmaker NVIDIA Corp. (NASDAQ: NVDA) to ChatGPT-parent OpenAI last week, while arguing that critics are missing the point of how value is created and measured in such partnerships. ‘A Lot More Efficient...

Investor Martin Shkreli, popularly known as “Pharma Bro,” is once again criticizing quantum computing company, IONQ Inc. (NYSE: IONQ), for comments made by its CEO, Peter Chapman. The ‘Craziest’ Statement From A CEO On Wednesday, in a post on X, Shkreli called out Chapman...

Hedge fund manager George Noble criticized iBuying platform Opendoor Technologies Inc. (NASDAQ:OPEN), which has seen a monumental 1,776% rally since hitting an all-time low in late June. The Business Model ‘Does Not Work’ In a post on X, Noble, who has founded two billion-dollar hedge...

Investor Martin Shkreli, popularly known as “Pharma Bro,” pushed back against criticism on this recent short position on iBuying platform Opendoor Technologies Inc. (NASDAQ:OPEN), which is rallying amid the Federal Reserve’s rate cuts on Wednesday. OPEN shares are climbing with...

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. What Happened: On Saturday, in a post on X, Shkreli forecasted a potential 90% drop in the shares of biotech startup, Inmune Bio Inc. (NASDAQ:...

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. What Happened: On Saturday, in a post on X, Shkreli forecasted a potential 90% drop in the shares of biotech startup, Inmune Bio Inc. (NASDAQ:...